David H Drewry
Overview
Explore the profile of David H Drewry including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
98
Citations
1778
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Newman J, Gavard A, Imprachim N, Aitkenhead H, Sheppard H, Te Poele R, et al.
Nat Commun
. 2025 Feb;
16(1):1596.
PMID: 39952925
Brachyury is a transcription factor that plays an essential role in tumour growth of the rare bone cancer chordoma and is implicated in other solid tumours. Brachyury is minimally expressed...
2.
DeLiberty J, Roach M, Stalnecker C, Robb R, Schechter E, Pieper N, et al.
Cancer Res
. 2025 Feb;
PMID: 39932818
Pancreatic ductal adenocarcinoma (PDAC) is characterized by KRAS- and autophagy-dependent growth. Inhibition of the KRAS-RAF-MEK-ERK pathway enhances autophagic flux and dependency, and concurrent treatment with the nonspecific autophagy inhibitor chloroquine...
3.
Shirley D, Nandakumar M, Cabrera A, Yiu B, Puumala E, Liu Z, et al.
bioRxiv
. 2025 Jan;
PMID: 39829896
is a growing health concern as the leading causal agent of systemic candidiasis, a life-threatening fungal infection with a mortality rate of ~40% despite best available therapy. Yck2, a fungal...
4.
Rinderle C, Baker C, Lagarde C, Nguyen K, Al-Ghadban S, Matossian M, et al.
Anticancer Drugs
. 2024 Dec;
36(1):39-48.
PMID: 39671264
Triple-negative breast cancer (TNBC) is a highly invasive breast cancer subtype that is challenging to treat due to inherent heterogeneity and absence of estrogen, progesterone, and human epidermal growth factor...
5.
Kaiser J, Risteska A, Muller A, Sun H, Lei B, Nay K, et al.
Biol Psychiatry
. 2024 Oct;
97(5):439-449.
PMID: 39442785
Although the precise underlying cause(s) of autism spectrum disorder remain unclear, more than 1000 rare genetic variations are associated with the condition. For many people living with profound autism, this...
6.
Ong H, Yang X, Smith J, Taft-Benz S, Howell S, Dickmander R, et al.
Molecules
. 2024 Sep;
29(17).
PMID: 39275006
The host kinase casein kinase 2 (CSNK2) has been proposed to be an antiviral target against β-coronaviral infection. To pharmacologically validate CSNK2 as a drug target in vivo, potent and...
7.
Bashore F, Min S, Chen X, Howell S, Rinderle C, Morel G, et al.
ACS Med Chem Lett
. 2024 Aug;
15(8):1325-1333.
PMID: 39140040
Acylaminoindazole-based inhibitors of CDKL2 were identified via analyses of cell-free binding and selectivity data. Compound was selected as a CDKL2 chemical probe based on its potent inhibition of CDKL2 enzymatic...
8.
Ong H, Yang X, Smith J, Dickmander R, Brown J, Havener T, et al.
J Med Chem
. 2024 Jul;
67(14):12261-12313.
PMID: 38959455
The pyrazolo[1,5-]pyrimidine scaffold is a promising scaffold to develop potent and selective CSNK2 inhibitors with antiviral activity against β-coronaviruses. Herein, we describe the discovery of a 1,2,4-triazole group to substitute...
9.
Bashore F, Min S, Chen X, Howell S, Rinderle C, Morel G, et al.
bioRxiv
. 2024 May;
PMID: 38798634
Acylaminoindazole-based inhibitors of CDKL2 were identified via analyses of cell-free binding and selectivity data. Compound was selected as a CDKL2 chemical probe based on its potent inhibition of CDKL2 enzymatic...
10.
Asquith C, East M, Laitinen T, Alamillo-Ferrer C, Hartikainen E, Wells C, et al.
Eur J Med Chem
. 2024 Apr;
271:116357.
PMID: 38636130
The oxindole scaffold has been the center of several kinase drug discovery programs, some of which have led to approved medicines. A series of two oxindole matched pairs from the...